GlassScriptPhysician profile
Hilary Shoemaker
NPI 1679052260
$1,746.81
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $695 · 2022: $830 · 2023: $208 · 2024: $13.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $212.68 | 2021-2022 | |
| Lilly USA, LLC | $131.22 | 2021-2022 | |
| Novo Nordisk INC | $85.68 | 2021-2023 | Wegovy |
| Sunovion Pharmaceuticals INC. | $82.24 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $63.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.60 | 2021 | |
| Astellas Pharma US INC | $55.02 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $50.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $48.70 | 2021 | |
| Collegium Pharmaceutical, INC. | $43.12 | 2021 | |
| Amgen INC. | $40.58 | 2022 | |
| Indivior INC. | $38.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.31 | 2021-2022 | |
| Janssen Biotech, INC. | $32.95 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.12 | 2021 | |
| Allergan, INC. | $31.08 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.46 | 2022 | |
| Eisai INC. | $27.36 | 2021 | |
| Currax Pharmaceuticals LLC | $26.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.15 | 2021 | |
| Nestle Healthcare Nutrition INC. | $22.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.62 | 2021 | |
| Bausch Health US, LLC | $19.86 | 2021 | |
| Glaxosmithkline, LLC. | $15.61 | 2021 | |
| Amarin Pharma, INC. | $15.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2021 | |
| Phadia US INC. | $14.50 | 2021 | |
| Mylan Specialty L.P. | $11.17 | 2021 | |
| Sumitomo Pharma America, INC. | $11.03 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilary Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.